Imaging Biometrics Limited

Board/Management Information • Nov 24, 2025

National Storage Mechanism | Additional information

RNS Number : 7342I

Imaging Biometrics Limited

24 November 2025

Imaging Biometrics Limited

("IBAI" or the "Company")

Board Changes

The Company announces that Dr Al Musella will step down from the Board of Directors with effect from 31 December 2025.

Although Dr Musella will no longer serve on the IBAI Board, he will remain closely involved with IBAI's wholly owned subsidiary, Imaging Biometrics LLC in a more direct and frequent capacity. Dr Musella will assume the role of Medical Advisor, providing clinical insight and strategic input to product development and marketing efforts.

The Board looks forward to continuing its collaboration with Dr Musella in this enhanced advisory role and thanks him for his ongoing commitment to the business.

--ENDS-

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

Imaging Biometrics Ltd Trevor Brown/Dr Al Musella/Brett Skelly/Michael Schmainda Tel: 020 7469 0930
AlbR Capital Limited (Broker) Lucy Williams/Heena Karani Tel: 020 7220 9797

About Imaging Biometrics® LLC:  IB is a wholly owned subsidiary of Imaging Biometrics Limited, (LON: IBAI), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com. Follow IB on X, @ImgBiometrics.  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAUSVKRVUUAURA